Back to top
more

Repligen (RGEN)

(Real Time Quote from BATS)

$132.17 USD

132.17
318,401

-2.83 (-2.10%)

Updated Jul 17, 2024 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Repligen (RGEN) Looks Good: Stock Adds 6.1% in Session

by Zacks Equity Research

Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination

by Zacks Equity Research

J&J (JNJ) files regulatory application in the United States and Europe seeking label expansion of Darzalex Faspro in combination with pomalidomide and dexamethasone for treating multiple myeloma.

Sanghamitra Saha headshot

5 Top Stocks to Buy on Earnings Beat Potential

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III

by Zacks Equity Research

AstraZeneca's (AZN) pipeline candidate tezepelumab achieves the primary goal in phase III NAVIGATOR study for addressing patients with severe, uncontrolled asthma.

Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes

by Indrajit Bandyopadhyay

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Genocea to Initiate a Phase I/II Oncology Study on GEN-011

by Zacks Equity Research

Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.

Why Repligen Corporation (RGEN) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).

Why Is Repligen (RGEN) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's NDA Filing for Migraine Candidate in Q4 on Track

by Zacks Equity Research

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline

by Zacks Equity Research

Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.

Sanghamitra Saha headshot

Looking for Earnings Beat? Buy These 5 Stocks With Potential

by Sanghamitra Saha

These top-ranked stocks are likely to beat on their bottom line in the next releases.

Albireo Down on Unimpressive Data From Mid-Stage NASH Study

by Zacks Equity Research

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%

by Zacks Equity Research

Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for August 13th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 13th.

Zacks.com featured highlights include: YETI, JD.com, Repligen, Shopify and Noble Energy

by Zacks Equity Research

Zacks.com featured highlights include: YETI, JD.com, Repligen, Shopify and Noble Energy

Sanghamitra Saha headshot

5 Top Stocks Likely to Beat Earnings Estimates This Season

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases.

Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Repligen (RGEN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (RGEN) Outperforming Other Medical Stocks This Year?

EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. RGEN: Which Stock Is the Better Value Option?